FDA approves Regeneron antibody cocktail for COVID-19 prevention

The FDA revised its emergency use authorization for Regeneron’s COVID-19 antibody cocktail July 30, allowing the treatment to be used as a post-exposure prophylaxis for COVID-19 in individuals who are at high risk for progression to severe COVID-19.

Advertisement
Katie Adams

The treatment, a cocktail of casirivimab and imdevimab, was granted FDA emergency use authorization in November.

When announcing the revision to its emergency approval, the FDA stipulated that the antibody cocktail is authorized as a COVID-19 prophylaxis only for individuals who have been exposed to the virus. The agency also said the treatment is not a substitute for a COVID-19 vaccine.

How rural health systems are scaling ambient AI — fast

Recommended Whitepaper

Advertisement

Next Up in Pharmacy

  • 75 drugs currently in shortage: FDA

    The number of active drug shortages has declined sharply since June, according to the FDA’s drug shortage database. Seventy-five drugs…

    By: Mackenzie Bean

  • 6 recent updates on GLP-1 drugs

    From payer shifts to regulatory milestones, GLP-1 therapies for obesity and diabetes continued to reshape the healthcare landscape in December.…

    By: Ella Jeffries

  • 73 drugs lost exclusivity in 2025

    In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval…

    By: Paige Twenter
Advertisement

Comments are closed.